BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 7581089)

  • 1. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
    Scheid C; Pettengell R; Ghielmini M; Radford JA; Morgenstern GR; Stern PL; Crowther D
    Bone Marrow Transplant; 1995 Jun; 15(6):901-6. PubMed ID: 7581089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
    Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W
    Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
    Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
    Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
    Brice P; Marolleau JP; Dombret H; Lepage E; Baruchel A; Adam M; Miclea JM; Sitthy X; Gisselbrecht C
    Bone Marrow Transplant; 1992 May; 9(5):337-42. PubMed ID: 1352162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
    Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
    Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
    Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
    In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkins's disease or non-Hodgkin's lymphoma.
    Fitoussi O; Simon D; Brice P; Makke J; Scrobohaci ML; Bibi Triki T; Hennequin C; Fermé C; Gisselbrecht C
    Bone Marrow Transplant; 1999 Oct; 24(7):747-55. PubMed ID: 10516678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: a study by the non-Hodgkin's Lymphoma Co-operative Study Group.
    Santini G; Coser P; Congiu AM; Salvagno L; De Souza C; Sertoli MR; Olivieri A; Chisesi T; Rubagotti A; Truini M; Contu A; Porcellini A; Zambaldi G; Nati S; Marino G; Rizzoli V
    Haematologica; 2000 Feb; 85(2):160-6. PubMed ID: 10681723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
    Moskowitz CH; Glassman JR; Wuest D; Maslak P; Reich L; Gucciardo A; Coady-Lyons N; Zelenetz AD; Nimer SD
    Clin Cancer Res; 1998 Feb; 4(2):311-6. PubMed ID: 9516916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow.
    Talmadge JE; Reed E; Ino K; Kessinger A; Kuszynski C; Heimann D; Varney M; Jackson J; Vose JM; Bierman PJ
    Bone Marrow Transplant; 1997 Jan; 19(2):161-72. PubMed ID: 9116614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis.
    Pettengell R; Morgenstern GR; Woll PJ; Chang J; Rowlands M; Young R; Radford JA; Scarffe JH; Testa NG; Crowther D
    Blood; 1993 Dec; 82(12):3770-7. PubMed ID: 7505124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
    Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
    Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
    Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
    Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
    Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracellular IL-4/IFN-gamma producing peripheral T lymphocyte subsets in B cell non-Hodgkin's lymphoma patients.
    Gergely L; Aleksza M; Váróczy L; Ponyi A; Sipka S; Illés A; Szegedi G
    Eur J Haematol; 2004 May; 72(5):336-41. PubMed ID: 15059068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation.
    Smith RJ; Sweetenham JW
    Exp Hematol; 1995 Dec; 23(14):1581-8. PubMed ID: 8542950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.